{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01086",
      "entity_text" : "CD44+",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:11707110",
      "entity_text" : "trametinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "We showed that selumetinib and trametinib reduced antigen specific activation (CD44+) in a dose dependent manner in both continuous and pulsatile treatments, which suggests a critical role of pERK in CD8+ T cell priming.",
  "reading_complete" : "2020-08-08T10:51:41Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T10:49:20Z",
  "trigger" : "reduced",
  "evidence" : [ "trametinib reduced antigen-specific activation (CD44+" ],
  "pmc_id" : "6719696",
  "score" : 0
}